At a Glance
- Companies: GSK plc; RAPT Therapeutics, Inc.
- Location: London, UK (GSK); San Francisco, CA, USA (RAPT)
- Deal value: US$2.2 billion all‑cash acquisition
- Focus area: Oral CCR4 antagonist for food allergies and immunology expansion
- Next steps: Complete acquisition; advance RAPT’s clinical pipeline
What happened?
GSK has agreed to acquire RAPT Therapeutics for approximately US$2.2 billion in an all‑cash transaction, securing full rights to RAPT’s experimental oral therapy targeting food allergies. The deal adds a novel CCR4 antagonist to GSK’s immunology portfolio, with GSK assuming control of RAPT’s broader pipeline of oral small molecules for inflammatory diseases.
Why does it matter?
Food allergies affect millions globally with limited therapeutic options beyond avoidance and emergency epinephrine, creating high unmet need for disease‑modifying oral treatments. GSK gains a differentiated CCR4 inhibitor that could modulate allergic responses at the T‑cell level, complementing its established respiratory/immunology franchises (e.g. Nucala, Xolair) and positioning it for growth in a $20+ billion allergy market.
Who’s behind it?
RAPT Therapeutics specialises in oral small‑molecule immunology modulators, with its lead CCR4 antagonist in phase 2 for atopic dermatitis and food allergies showing promising biomarker modulation. GSK continues aggressive immunology M&A following Arexvy RSV and Blenrep myeloma investments.
How was it achieved?
GSK will pay a premium to RAPT’s market cap, acquiring the full company and pipeline. RAPT shareholders receive cash consideration, with GSK integrating assets into its global R&D and commercial infrastructure for accelerated clinical advancement.
What’s next?
GSK will prioritise phase 2b/3 trials in food allergy and atopic dermatitis, leveraging its dermatology/immunology expertise for regulatory filings and potential label expansions. The acquisition signals continued Big Pharma appetite for immunology despite crowded incretin markets.
What are people saying?
GSK executives described the deal as securing “next‑generation oral immunology” for underserved allergy indications. Analysts project RAPT’s lead asset at $1–2bn peak sales, validating GSK’s premium valuation amid pipeline diversification needs.